Clinical Trials

A Phase I Trial Assessing the Feasibility of Romidepsin Combined with Brentuximab Vedotin for Patients with Requiring Systemic Therapy for Cutaneous T-cell Lymphoma

Study ID
Fox Chase HM-085

NCT Number
NCT02616965 (Click on the NCT number for more information about the trial)

Research Study Number

Principle Investigator
Dr. Tatyana Feldman


Fox Chase

Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at

Apply Now